Protection by Apomorphine in Two Independent Models of Acute Inhibition of Oxidative Metabolism in Rodents

References

• Hunter AJ, Mackay KB, Rogers DC. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents?. Trends Pharmacol Sci 1998; 19: 59–66
   PubMed Web of Science ®Google Scholar
• De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?. Trends Neurosci 1999; 22: 535–40
   PubMed Web of Science ®Google Scholar
• Wenning GK, Bosch S, Luginger E, Wagner M, Poewe W. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Adv Neurol 1999; 80: 545–548
   PubMedGoogle Scholar
• Suzuki R, Yamaguchi T, Kirino T, Orzi F, Klatzo I. The effects of 5-minute ischemia in Mongolian gerbils: I. Blood-brain barrier, cerebral blood flow, and local cerebral glucose utilization changes. Acta Neuropathol (Berl) 1983; 60: 207–216
   PubMed Web of Science ®Google Scholar
• Kondo T, Ito T, Sugita Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann NY Acad Sci 1994; 738: 222–229
   PubMed Web of Science ®Google Scholar
• Liu XH, Kato H, Chen T, Kato K, Itoyama Y. Bromocriptine protects against delayed neuronal death of hippocampal neurons following cerebral ischemia in the gerbil. J Neurol Sci 1995; 129: 9–14
   PubMed Web of Science ®Google Scholar
• Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 1998; 12: 905–912
   PubMed Web of Science ®Google Scholar
• Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994; 657: 207–213
   PubMed Web of Science ®Google Scholar
• Felten DL, Felten SY, Fuller RW, Romano TD, Smalstig EB, Wong DT, Clemens JA. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol Aging 1992; 13: 339–51
   PubMed Web of Science ®Google Scholar
• O'Neill MJ, Hicks CA, Ward MA, Cardwell GP, Reymann JM, Allain H, Bentue-Ferrer D. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia. Eur J Pharmacol 1998; 352: 37–46
   PubMed Web of Science ®Google Scholar
• Opacka-Juffry J, Wilson AW, Blunt SB. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res 1998; 810: 27–33
   PubMed Web of Science ®Google Scholar
• Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1999; 127: 1696–1702
   PubMed Web of Science ®Google Scholar
• Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999; 838: 51–59
   PubMed Web of Science ®Google Scholar
• Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997; 104: 209–228
   PubMed Web of Science ®Google Scholar
• Hall ED, Andrus PK, Oostveen JA, Althaus JS, VonVoigtlander PF. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996; 742: 80–88
   PubMed Web of Science ®Google Scholar
• Ling ZD, Robie HC, Tong CW, Carvey PM. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharmacol Exp Ther 1999; 289: 202–210
   PubMed Web of Science ®Google Scholar
• Caldwell MA, Reymann JM, Allain H, Leonard BE, Bentue-Ferrer D. Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global cerebral ischemia in rats. Brain Res 1997; 771: 305–318
   PubMed Web of Science ®Google Scholar
• Delbarre B, Delbarre G, Rochat C, Calinon F. Effect of piribedil, a D-2 dopaminergic agonist, on dopamine, amino acids, and free radicals in gerbil brain after cerebral ischemia. Mol Chem Neuropathol 1995; 26: 43–52
   PubMedGoogle Scholar
• Gassen M, Gross A, Youdim MB. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov Disord 1998; 13: 661–667
   PubMed Web of Science ®Google Scholar
• Grunblatt E, Mandel S, Gassen M, Youdim MB. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. J Neural Transm Suppl 1999; 55: 57–70
   PubMedGoogle Scholar
• Grunblatt E, Mandel S, Maor G, Youdim MB. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J Neurochem 2001; 77: 146–156
   PubMed Web of Science ®Google Scholar
• Carvey PM, McGuire SO, Ling ZD. Neuroprotective effects of D3 dopamine receptor agonists 2001; 7: 213–223
   Google Scholar
• Grunblatt E, Mandel S, Berkuzki T, Youdim MB. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 1999; 14: 612–618
   PubMed Web of Science ®Google Scholar
• Caldwell MA, Reymann JM, Bentue-Ferrer D, Allain H, Leonard BE. The dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the rat. Neuropsychobiology 1996; 34: 117–124
   PubMed Web of Science ®Google Scholar
• Agid Y, Javoy F, Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigro-striatal dopaminergic system in the rat. Nat New Biol 1973; 245: 150–151
   PubMedGoogle Scholar
• Melamed E, Hefti F, Wurtman RJ. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model. Isr J Med Sci 1982; 18(1)159–163
   PubMedGoogle Scholar
• Globus MY, Busto R, Dietrich WD, Martinez E, Valdes I, Ginsberg MD. Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gamma-aminobutyric acid studied by intracerebral microdialysis. J Neurochem 1988; 51: 1455–1464
   PubMed Web of Science ®Google Scholar
• Lin MT, Kao TY, Chio CC, Jin YT. Dopamine depletion protects striatal neurons from heatstroke-induced ischemia and cell death in rats. Am J Physiol 1995; 269: H487–H490
   PubMed Web of Science ®Google Scholar
• Sonsalla PK, Gibb JW, Hanson GR. Roles of D1 and D2 dopamine receptor subtypes in mediating the methamphetamine-induced changes in monoamine systems. J Pharmacol Exp Ther 1986; 238: 932–937
   PubMed Web of Science ®Google Scholar
• Battaglia G, Gesi M, Lenzi P, Busceti CL, Soldani P, Orzi F, et al. Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity. Ann NY Acad Sci 2002; 965: 254–266
   PubMed Web of Science ®Google Scholar
• Fornai F, Battaglia G, Gesi M, Orzi F, Nicoletti F, Ruggieri S. Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res 2001; 898: 27–35
   PubMed Web of Science ®Google Scholar
• Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998; 44: S167–174
   Web of Science ®Google Scholar
• Ling ZD, Tong CW, Carvey PM. Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures. Brain Res 1998; 79: 137–145
   Google Scholar
• Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001; 65: 135–172
   PubMed Web of Science ®Google Scholar
• Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 1998; 39: 167–180
   PubMed Web of Science ®Google Scholar
• Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol Exp (Wars) 1999; 59: 1–8
   PubMed Web of Science ®Google Scholar
• Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999; 156: 50–61
   PubMed Web of Science ®Google Scholar
• Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999; 46: 598–605
   PubMed Web of Science ®Google Scholar
• McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285–1291
   PubMed Web of Science ®Google Scholar